Page 30 - Pfizer

S&P 500 gains on promising Covid-19 vaccine data, more stimulus hopes

US drugmaker Pfizer and German biotech firm BioNTech reported additional data from their experimental Covid-19 vaccine that showed it was safe and induced an immune response in patients

Pfizer-BioNTech potential Covid-19 vaccine shows promise in additional data

The companies said the data also demonstrated an induction of high level of T-cell response against the novel coronavirus

Britain signs deals with Pfizer, BioNTech, Valneva for Covid-19 vaccines

Deals follow a previously announced agreement with AstraZeneca for the firm to produce 100 million doses of its potential vaccine being developed in partnership with the University of Oxford

Early trial of Covid-19 vaccines by Pfizer, BioNtech promising: Scientists

The research said patients treated with the vaccine candidate produced nearly 1.8 to 2.8 fold greater levels of antibodies that could neutralise SARS-CoV-2

Pfizer, BioNTech's Covid-19 drug shows encouraging results in early tests

With its other potential candidates still in the earliest stage of testing, Pfizer aims to open a large-scale study this summer but can't yet say which shot is best to include

S&P, Nasdaq higher on Covid-19 vaccine hopes, improving economic data

A Covid-19 vaccine developed by Pfizer Inc and German biotech firm BioNTech showed promise and was found to be well tolerated in early-stage human trials

J&J to begin human trials of Covid-19 vaccine in second half of July

The company has already signed deals with the US government to create enough manufacturing capacity to produce more than 1 billion doses of its vaccine through 2021

Pfizer to outsource some drug production, focus on coronavirus vaccine

Pfizer and German partner BioNTech SE (22UAy.F) said on Tuesday they have begun delivering doses of their coronavirus vaccine candidates for initial human testing in the United States.

Covid-19 treatment: AIIMS to conduct clinical trials of plasma therapy

The AIIMS director stresses on the need to have good and well-conducted research trials before the therapy is recommended for routine use

Pfizer surges 10% on special dividend of Rs 320 per share

The company has fixed May 8, 2020 as the record date for ascertaining eligible shareholders who would get the dividend of Rs 320 per share.

Patents vs the pandemic

We should question the wisdom and morality of a system that silently condemns millions of human beings to suffering

Coronavirus outbreak: Pfizer-BioNTech vaccine cleared for human tests

The trial, only the fourth worldwide of a vaccine targeting the virus, will be initially conducted on 200 healthy people aged 18 to 55 years in first stage

Early studies of potential coronavirus treatment show promise: Pfizer

It also finalised a plan to develop a coronavirus vaccine in partnership with German drugmaker BioNTech SE and said the companies hope to produce millions of vaccines by the end of 2020.

Big Pharma's addiction to profit

Book review of PHARMA: Greed, Lies, and the Poisoning of America

Pfizer may work with BioNTech to develop coronavirus vaccine: R&D head

(Reuters) - Pfizer Inc is considering a collaboration with German drugmaker BioNTech SE <22UAy.F> to develop vaccines for the coronavirus using BioNTech's mRNA-based drug development platform, Pfizer's R&D head told Reuters on Thursday.

Pfizer warns of hit to financial results on continued coronavirus outbreak

The outbreak that began in Wuhan at the end of last year has killed over 2,700 in China, with over 78,000 confirmed cases of infection, and has now spread to several other countries.

Pfizer Q3 net profit climbs 5%, operational revenue up at Rs 514 cr

The company had posted a net profit of Rs 131.94 crore for the corresponding period of the previous fiscal, Pfizer Ltd said in a filing to BSE.

Pfizer planning initial public offering of GSK consumer venture in four yrs

Albert Bourla, CEO of Pfizer, discussed the time frame for the IPO at the JPMorgan Healthcare Conference in San Francisco on Tuesday

Legacy pharma brands spin gold for GSK, Pfizer; keep newcomers off the turf

Repositioning an old brand helps expand the footprint, say analysts

Drugmakers from Pfizer to GSK to hike US prices up to 10% on over 200 drugs

More price increases are expected to be announced later this week, which could affect the median and range.